Seagen, a wholly owned subsidiary of Pfizer $PFE
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS12
PHASE 3 / 2-36
RECRUITING1
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO67%
Delay Index: of 12 active trials registered more than a year ago, 8 have moved their primary completion (readout) date by more than 6 months since first registration (median +10.2 months). See all sponsors →
Open Seagen, a wholly owned subsidiary of Pfizer on the live radar map → 📅 $PFE readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| tucatinib NCT03975647 |
P3 | Active, not recruiting | HER2-positive Breast Cancer | 466 | 2023-06-29 (-9 mo) |
| tucatinib NCT04579380 |
P2 | Active, not recruiting | Uterine Neoplasms; Uterine Cervical Neoplasms | 217 | 2023-11-01 (+9 mo) |
| tucatinib NCT04430738 |
P2 | Active, not recruiting | Colorectal Carcinoma; Gastric Adenocarcinoma | 40 | 2024-07-31 (+38 mo) |
| HER2CLIMB-05 NCT05132582 |
P3 | Active, not recruiting | HER2 Positive Breast Cancer | 654 | 2025-09-05 (+10 mo) |
| ECHELON-3 NCT04404283 |
P3 | Active, not recruiting | Diffuse Large B-cell Lymphoma | 240 | 2026-01-23 (+38 mo) |
| innovaTV 207 NCT03485209 |
P2 | Active, not recruiting | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | 350 | 2026-03-20 (+72 mo) |
| disitamab vedotin NCT06003231 |
P2 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms | 120 | 2026-03-27 (-2 mo) |
| sigvotatug vedotin NCT06012435 |
P3 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung | 762 | 2026-05-18 (-6 mo) |
| disitamab vedotin NCT04879329 |
P2 | Recruiting | Urothelial Carcinoma | 372 | 2026-12-11 (+46 mo) |
| disitamab vedotin NCT05911295 |
P3 | Active, not recruiting | Urothelial Carcinoma | 412 | 2027-01-29 (+7 mo) |
| MOUNTAINEER-03 NCT05253651 |
P3 | Active, not recruiting | Colorectal Neoplasms | 400 | 2027-12-31 (+28 mo) |
| disitamab vedotin NCT06157892 |
P2 | Active, not recruiting | Breast Neoplasms; Gastroesophageal Junction Adenocarcinoma | 54 | 2029-07-28 (-6 mo) |